0000000001239155

AUTHOR

M. Wirth

showing 5 related works from this author

Postersitzung 9: Therapeutische Alternativen beim Harnleiterstein

1988

In der heutigen Therapie des Harnleitersteines dominiert eindeutig die ESWL. Bei erfolgloser ESWL oder bei speziellen Indikationen wie grose obere Harnleitersteine oder Steine in Projektion auf die Ileosacralfuge kommen die endourologischen Masnahmen zum Tragen. Die Indikationsbreite fur den Einsatz einer Schlinge ist insbesondere wegen der Gefahr der aufsteigenden Infekte nur noch sehr gering. Da selbst bei anatomischen Veranderungen diese haufig durch endourologische Masnahmen beseitigt werden konnen, steht die offene Schnittoperation im Rahmen der Therapie des Harnleitersteines an letzter Stelle.

researchProduct

Postersitzung 2: Das metastasierte Prostatakarzinom

1988

Weltweit sind betrachtliche Unterschiede in der Morbiditat und Mortalitat des Prostatacarcinoms bekannt. Die hochste Inzidenz besteht bei der schwarzen Bevolkerung in den USA, Asiaten hingegen erkranken nur sehr selten.

researchProduct

Postersitzung 6: Extrakorporale Stoßwellenlithotripsie (ESWL) bei komplizierter Urolithiasis

1988

Die Nierensteinbehandlung hat sich mit Einfuhrung von PCNL und ESWL innerhalb weniger Jahre dramatisch gewandelt. Die Kombination von PCNL plus ESWL minimiert die Nachteile beider Techniken, die sie in ihrer alleinigen Anwendung bei der Behandlung von Ausgussteinen aufweisen. Uber unsere ersten Erfahrungen mit diesem Therapiekonzept haben wir bereits berichtet [1]. Bisher ist jedoch noch unklar, welche Spatergebnisse in diesen mit PCNL plus ESWL behandelten Patienten erzielt werden. In dieser Studie haben wir daher Patienten nachuntersucht, die 1984 und 1985 an unserer Klinik wegen Ausgussteinen kombiniert mit PCNL plus ESWL behandelt worden waren.

researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - Results …

2013

Objectives To assess the prognostic impact of time to recurrence (TTR) on cancer-specific survival (CSS) after recurrence in patients with renal cell carcinoma (RCC) undergoing radical nephrectomy or nephron-sparing surgery. To analyse differences in clinical and histopathological criteria between patients with early and late recurrence. Patients and Methods Of 13 107 patients with RCC from an international multicentre database, 1712 patients developed recurrence in the follow-up (FU), at a median (interquartile range) of 50.1 (25-106) months. In all, 1402 patients had recurrence at ≤5 years (Group A) and 310 patients beyond this time (Group B). Differences in clinical and histopathological…

Malerenal cell carcinomaTime FactorsTime FactorDatabases FactualPrognosiUrologyprognostic parameterearly recurrencetime to recurrencecancer-specific survivalRetrospective Studielate recurrencenephrectomyHumanscancer survivalCarcinoma Renal Cellrenal cell carcinoma (RCC); time to recurrence; early recurrence; late recurrence; prognostic parameters; cancer-specific survival; nephrectomyAgedRetrospective StudiesKidney NeoplasmMiddle Agedprognostic parametersPrognosisKidney NeoplasmsSurvival Ratecancer survival; early recurrence; late recurrence; nephrectomy; prognostic parameters; renal cell carcinomacancer-specific survival; early recurrence; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma; time to recurrenceFemaleNeoplasm Recurrence Localrenal cell carcinoma (rcc)cancer-specific survival; early recurrence; late recurrence; nephrectomy; prognostic parameters; renal cell carcinoma (rcc); time to recurrenceHuman
researchProduct